The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Bristol-Myers Squibb's revenues will drop -25.8% and EPS will contract -31.1%.
The average estimate for revenue is $3.97 billion. On the bottom line, the average EPS estimate is $0.42.
Last quarter, Bristol-Myers Squibb logged revenue of $4.44 billion. GAAP reported sales were 18% lower than the prior-year quarter's $5.43 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.48. GAAP EPS of $0.38 for Q2 were 27% lower than the prior-year quarter's $0.52 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 75.3%, 220 basis points better than the prior-year quarter. Operating margin was 27.1%, 630 basis points worse than the prior-year quarter. Net margin was 14.5%, 210 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $17.92 billion. The average EPS estimate is $1.93.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,699 members out of 1,809 rating the stock outperform, and 110 members rating it underperform. Among 476 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 457 give Bristol-Myers Squibb a green thumbs-up, and 19 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bristol-Myers Squibb is hold, with an average price target of $34.85.
Can your portfolio provide you with enough income to last through retirement? You'll need more than Bristol-Myers Squibb. Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks." Click here for instant access to this free report.
- Add Bristol-Myers Squibb to My Watchlist.